{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03386513","nct_id":"NCT03386513","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03386513. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Escalation: IMGN632 was administered by IV on 2 different schedules for participants with relapsed/refractory AML, ALL, or BPDCN.\n\nExpansion: IMGN632 was administered by IV:\n\n* Cohort 1: Relapsed or refractory BPDCN participants who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN)\n* Cohort 2: Relapsed AML\n* Cohort 3: Relapsed or refractory ALL\n* Cohort 4: Other relapsed or refractory hematologic malignancies\n* Cohort 5: Relapsed or refractory AML at alternate dose or schedule\n* Cohort 6: Pivotal cohort for frontline BPDCN participants who have not received prior systemic therapy and participants with frontline BPDCN who have prior or concomitant hematologic malignancy (PCHM) and have not received prior systemic therapy.","label":"Escalation and Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm","Myeloproliferative Neoplasm"],"enrollment":{"count":179,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"IMGN632","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-04","lead_sponsor":"AbbVie","official_title":"A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2024-10-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participants","timeFrame":"Up to approximately 81 months"}],"references":[{"citation":"Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, Maisano V, Martinelli G, DeAngelo DJ, Derenzini E, Du Y, Lakshmikanthan S, Potluri J, Kantarjian HM, Daver NG. Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2026 Apr;44(10):861-873. doi: 10.1200/JCO-25-02083. Epub 2026 Feb 11.","pmid":"41671533","type":"DERIVED"},{"citation":"Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, Sweet KL, Pemmaraju N, Lane AA, Torres-Minana L, Thompson JE, Konopleva MY, Sloss CM, Watkins K, Bedse G, Du Y, Malcolm KE, Zweidler-McKay PA, Kantarjian HM. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar;25(3):388-399. doi: 10.1016/S1470-2045(23)00674-5.","pmid":"38423051","type":"DERIVED"}],"start_date":{"date":"2018-01-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","url":"https://clinicaltrials.gov/study/NCT03386513"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03386513"}